Home About us Contact
|
Home About us Contact | ||
|
|
||
Macular Thickness (macular + thickness)
Kinds of Macular Thickness Selected AbstractsOptical coherence tomography is helpful in the diagnosis of foveal hypoplasiaACTA OPHTHALMOLOGICA, Issue 4 2010Gerd Holmström Abstract. Purpose:, To investigate whether optical coherence tomography (OCT) is helpful in the diagnosis of foveal hypoplasia in children. Methods:, Children with albinism and aniridia were examined with Stratus OCT 3 software 4.0.1 (Carl Zeiss Meditec, Dublin, California, USA). A qualitative examination of the macular area was performed with a 128 A-scans/second-single-scan. Macular thickness was measured quantitatively with an automatic fast macular map protocol. The average thickness/volume of the macula was presented as numerical values and as a false colour code in nine modified early treatment of diabetic retinopathy study (ETDRS) areas (A1,A9). A previously collected control group of children was used for comparison. Results:, Macular thickness in 13 children with albinism and three children with aniridia was measured with OCT. Comparison with healthy children in the same population was performed. Patients with albinism and aniridia had significantly thicker central macula (A1) and foveola than children in the control group. Conclusion:, OCT was found to be useful in the diagnosis of foveal hypoplasia in children. [source] Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration in treatment-naive patientsACTA OPHTHALMOLOGICA, Issue 7 2009Karen Bjerg Pedersen Abstract. Purpose:, To report the effects of intravitreal bevacizumab (Avastin®) in treatment-naive patients with exudative age-related macular degeneration (ARMD) assessed by visual acuity (VA), optical coherence tomography (OCT) and contrast sensitivity. Methods:, A prospective, uncontrolled, pilot study of 26 eyes of 26 patients, all previously treatment-naive to photodynamic therapy, argon laser or anti-vascular endothelial growth factor (VEGF), were treated with one or more intravitreal injections of 1.25 mg bevacizumab. Of the 26 patients, 15 (57.7%) had occult choroidal neovascularization (CNV), 6 (23.1%) had predominantly classic CNV and 5 (19.2%) had minimally classic CNV. Ophthalmic outcome measures included changes in standardized Early Treatment Diabetic Research Study (ETDRS) VA, contrast sensitivity and OCT. The patients were examined at baseline and 1 week, 6 weeks, 3 months and 6 months after the first injection. Re-treatment was given on an ,as needed' basis. Results:, Twenty-four eyes of 24 patients completed 6 months of follow-up. Two patients chose to discontinue the study. Mean ETDRS VA score improved from 55 letters at baseline to 60 letters at 1 week (P < 0.01) and to 61 letters at 6 weeks (P < 0.01). No significant improvement in VA from baseline was found after 3 and 6 months. Patients with pigment epithelial detachment (PED) had a significantly worse outcome in VA at 6 months. Contrast sensitivity improved from baseline to 3 or 6 months, but this improvement was not statistically significant. Mean macular thickness decreased significantly from baseline to all follow-up examinations (P < 0.01). Conclusion:, Mean ETDRS VA improved significantly after 1 and 6 weeks; thereafter, it remained stable throughout the study period. Macular thickness improved significantly at all time points. The results indicate that 1.25 mg intravitreal bevacizumab is associated with functional as well as morphological improvement among treatment-naive ARMD patients. [source] Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degenerationACTA OPHTHALMOLOGICA, Issue 6 2010Jost B. Jonas Acta Ophthalmol. 2010: 88: 630,634 Abstract. Purpose:, We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD). Methods:, The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 ± 1.8 mono-injections of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2,3 months after the intervention. Results:, Visual acuity improved significantly (p = 0.03) from 0.80 ± 0.40 logMAR prior to the combined injection to 0.65 ± 0.42 logMAR at 3 months after the injection. An improvement of , 1 Snellen line was found in eight subjects, an increase of , 2 lines in five subjects, and an improvement of , 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 ± 62 ,m to 220 ± 47 ,m (p = 0.03). At the 6-month follow-up examination, central retinal thickness had increased again to 319 ± 142 ,m, which was not significantly (p = 0.30) different from baseline measurements. Conclusions:, The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono-injections have failed to improve vision and reduce macular oedema. [source] Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age-related macular degenerationACTA OPHTHALMOLOGICA, Issue 6 2010Philippe Bonnin Acta Ophthalmol. 2010: 88: 641,645 Abstract. Purpose:, Angiogenic inhibitors, alone or combined with other therapies, are believed to represent a promising treatment for neovascularization in age-related macular degeneration (wet AMD). They can maintain or improve visual acuity (VA), at least for the first 2 years. However, evolution to retinal atrophy cannot be ruled out and it may be useful to assess the effects of antiangiogenic therapy on retinal and choroidal circulation. Methods:, We carried out a pilot study in 15 patients with wet AMD. Time-averaged mean blood flow velocities (BFVs) in the central retinal, temporal posterior ciliary and ophthalmic arteries (CRA, TPCA and OA) were measured by ultrasound imaging before and 4 weeks after a single intravitreal injection of 1.25 mg bevacizumab in 0.05 ml. Patients underwent two ophthalmic examinations, before and 4 weeks after injection, including VA measurement and optical coherence tomography (OCT3) examination. Results:, In treated eyes, bevacizumab injection was followed by a significant improvement in VA (from 20/125 to 20/80; p = 0.0214), and a decrease in mean central macular thickness (from 392 ± 96 ,m to 271 ± 50 ,m; p = 0.0038). Mean BFV decreased by 10% in the CRA (p = 0.0226), 20% in the TPCA (p = 0.0026) and 20% in the OA (p = 0.0003). No effect was observed in fellow eyes. Conclusions:, Intravitreal bevacizumab acutely improved VA and reduced central macular thickness in wet AMD. Ultrasound imaging revealed that BFVs decreased in all retrobulbar arteries, suggesting that after local diffusion, bevacizumab exerts a short-term regional effect. Bevacizumab might therefore induce hypoperfusion of the whole eye, which may correspond to a vascular side-effect. [source] 2122: Role of prophylactic topical nepafenac in prevention of post pars-plana vitrectomy macular edemaACTA OPHTHALMOLOGICA, Issue 2010S MISHRA Purpose To evaluate the effects of topical nepafenac in patients undergoing pars plana vitrectomy (PPV) with special emphasis on its role in post PPV macular edema. Methods 108 patients undergoing PPV were randomized to receive either topical nepafenac 0.3% (53 eyes) or placebo (55 eyes) from 3 days preoperatively till 4 weeks postoperative in addition to topical steroids and antibiotics in this single center investigator masked study. Optical coherence tomography (OCT) was done at week 2,4,6 and 8 post operatively. Results Patients taking nepafenac and those taking placebo had mean postoperative day 1 pain scores of 0.25 and 1.08 (P=0.03) and mean inflammation grades of 0.49 and 1.34 (P=0.002) respectively. Although centre subfield macular thickness (CSMT) was lesser in nepafenac group as compared to placebo group (260.56 µm Vs 270.70 µm at week 2, 228.44 µm Vs 236.21 µm at week 4, 215.02 µm Vs 218.74 µm at week 6 and 205.35 µm Vs 205.17 µm at week 8 respectively), the difference did not reach statistically significant levels (P>0.05) at any visit. There was also, no statistically significant improvement in best corrected visual acuity between the nepafenac group and the placebo group at any postoperative visit. Conclusion Although addition of 0.3% nepafenac decreased postoperative pain and inflammation, it did not reduce incidence of macular edema in patients undergoing PPV. Topical nepafenac was well tolerated and safe but did not improve visual recovery in this set of patients. [source] Prospective randomized comparative study of macular thickness following phacoemulsification and manual small incision cataract surgeryACTA OPHTHALMOLOGICA, Issue 4 2010Sambuddha Ghosh Abstract. Purpose:, To compare macular thickness following uncomplicated phacoemulsification with foldable acrylic lens and manual small incision cataract surgery (MSICS) with non-foldable polymethyl methacrylate (PMMA) lens implantation. Methods:, Prospective study was carried out with one eye each of 224 patients with senile cataract randomized into two groups, phacoemulsification and MSICS, by simple 1:1 randomization. Following surgery by either of the two methods, macular thickness was measured by optical coherence tomography (OCT) on the 1st, 7th, 42nd and 180th postoperative day. Main outcome measure was postoperative macular thickness. Results:, On the first postoperative day, central subfield mean thickness (CSMT) in MSICS group was 192.8 ± 17.9 ,m and that in phacoemulsification group was 192.1 ± 27.4 ,m, with no significant difference (p = 0.12). On the 7th day, CSMT in MSICS group (198.9 ± 21.4 ,m) was significantly (p = 0.04) more than that in phacoemulsification group (193.1 ± 19.3 ,m). On the 42nd day, CSMT in MSICS group was 207.8 ± 26.3 ,m and that in phacoemulsification group was 198.3 ± 23 ,m, the difference being significant (p = 0.007). Clinically macular oedema was not diagnosed in any of the patients at any visit. The increase in macular thickness was sub-clinical and did not affect final visual outcome in any patient. Conclusion:, In spite of the greater theoretical risk of increased postoperative inflammation following MSICS, there was no evidence of cystoid macular oedema, either clinically or on OCT. However, chance of sub-clinical increase in CSMT was more following MSICS compared to phacoemulsification. [source] Axonal loss occurs early in dominant optic atrophyACTA OPHTHALMOLOGICA, Issue 3 2010Dan Milea Abstract. Purpose:, This study set out to investigate retinal nerve fibre layer (RNFL) thickness and best corrected visual acuity (BCVA) in relation to age in healthy subjects and patients with OPA1 autosomal dominant optic atrophy (DOA). Methods:, We carried out a cross-sectional investigation of RNFL thickness and ganglion cell layer density in 30 healthy subjects and 10 patients with OPA1 DOA using optical coherence tomography (OCT). We then performed a regression analysis of RNFL thickness and BCVA versus age. Results:, Both healthy subjects and DOA patients demonstrated a gradual reduction in RNFL thickness with age; the relationship was best described statistically by a model that assumed a constant offset between the two groups. Best corrected VA decreased significantly with age in DOA patients, in whom BCVA was correlated with peripapillary RNFL thickness in the inferior and superior peripapillary quadrants and with total macular thickness at eccentricities of 500,3000 ,m. The observations were best described by a constant offset of 41.9 ,m separating the two groups and an annual decrease in RNFL thickness of 0.48 ,m (p < 0.0001). In patients with DOA, increasing age was associated with decreasing BCVA (p = 0.046). Conclusions:, This cross-sectional study found evidence of comparable age-related decreases in RNFL thickness in healthy subjects and in DOA patients, where the deficit in DOA patients is best described using a model that assumes the deficit between the groups does not vary with age. The gradual reduction of BCVA with age may be a consequence of a relative deficit in RNFL thickness that is established before the second decade of life. [source] A population-based study of macular thickness in full-term children assessed with Stratus OCT: normative data and repeatabilityACTA OPHTHALMOLOGICA, Issue 7 2009Urban Eriksson Abstract. Purpose:, We aimed to determine normal macular thickness values, assessed with optical coherence tomography (OCT), in a population of full-term children of normal birthweight. Methods:, A total of 56 children, aged 5,16 years, randomly chosen from the population register, were examined with Stratus OCT. Only children with visual acuity < 0.2 logMAR, spherical equivalent of , 3 to + 3 D and astigmatism < 2 D were included. The fast macular map protocol was used and three examinations were performed in each eye. One eye was then randomized for further analyses. Mean values for the nine ETDRS areas, foveal minimum thickness and macular volume were calculated for 55 eyes. Coefficients of variance and intraclass correlations were calculated for each area. Results:, All children co-operated well and no child was excluded for lack of concentration. Mean ± standard deviation central macular thickness was 204 ± 19 ,m. Mean total macular volume was 7.11 ± 0.35 mm3. No correlations were found between age, gender and macular thickness. Coefficients of variance were < 2% and intraclass correlations were > 0.9 in all areas, except the foveal minimum. Conclusions:, Normal values for macular thickness in healthy full-term children were reported. As the Stratus OCT provides normal values only for adults, these data are a better alternative for comparison with children with retinal abnormalities. We concluded that OCT is suitable for examining the retina in children aged 5,16 years and has the same high level of repeatability as in adults. [source] Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedemaACTA OPHTHALMOLOGICA, Issue 6 2009Giuseppe Querques Abstract. Purpose:, To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO). Methods:, We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow-up visit. Results:, Sixty-three eyes of 48 patients with a minimum of 6 months of follow-up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6-week follow-up. Most eyes (60/63) required a mean of 3.03 ± 0.9 repeated treatments, over a mean follow-up period of 6.7 ± 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less-defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best-defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less-defined PR band. Conclusion:, Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)-165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO. [source] RTVue Fourier-domain OCT: reproducibility of RNFLT and macular thickness measurementsACTA OPHTHALMOLOGICA, Issue 2009A GARAS Purpose To evaluate the reproducibility of peripapillary retinal nerve fiber layer thickness (RNFLT) and macular thickness (MT) measurements with the RTVue-100 Fourier-domain optical coherence tomography, and to determine the influence of pupil dilation, patients' experience in examinations and severity of glaucoma. Methods One eye of 14 normal subjects, 11 patients with moderate, 12 patients with severe glaucoma and 40 screening trial participants were imaged 5 times on the same day. For the hospital-based patients, the measurement series was repeated after pupil dilation and 3 months later. Results For the RNFLT and the MT parameters, intrasession intraclass correlation coefficient (ICC) varied between 93.9 and 99.0%, intrasession coefficient of variation (CV) between 1.95 and 5.69 %, and intratest variability between 3.11 and 9.13 µm. Most thickness values, all intrasession CV and intratest variability values and the signal strength index remained unchanged after pupil dilation. Most intrasession CV values increased significantly with increasing disease severity. Patients' experience in imaging examinations had no influence on intrasession CV. Intratest variability and intrasession CV represented 79.1 to 98.6 % and 77.1 to 95.0 % of test-retest variability and intervisit CV, respectively. Conclusion Reproducibility of RNFLT and MT measurement with the RTVue-100 OCT are satisfactory for clinical purposes both in normals and glaucoma patients. Pupil dilation and patients' experience in imaging examinations do not influence the reproducibility of the measurements clinically significantly. Commercial interest [source] Preterm and at term children: morphological and functional analysis of optic nerve and visual pathway with OCT, HRT and pVEPACTA OPHTHALMOLOGICA, Issue 2009R ANGELI Purpose To compare optic nerve morphology and visual function in 14 preterm children(mean gestational age:33,38) with normal cerebral ultrasound at birth and 15 at term children (mean gestational age:39,67). Methods Mean preterm age was 7,6 years, mean at term was 9,1 years. Children underwent to complete functional and morphological evaluation of Optic Nerve Head (ONH) with Heidelberg Retinal Tomography and Optical Coherence Tomography. The same children were evaluated at birth and at the time of morphological examinations by mean of transient and steady state pVEP. Results Mean visual acuity was 9,85 in the preterm, 10 in the at term children. HRT in preterm and at term children at term(n=28) preterm(n=25) P value mean sd mean sd Disc Area 2,5 0,7 2,34 0,68 0,38 Cup Area 0,50 0,44 0,58 0,47 0,51 Rim Area 2 0,45 1,76 0,37 0,047 C/D Area Ratio 0,18 0,12 0,22 0,14 0,23 C/D Linear Ratio 0,4 0,15 0,45 0,16 0,30 Mean RNFL Thick 0,2 0,07 0,24 0,2 0,26 Tab.1 A statistically significant reduction was found in preterm children as regard rim area (p=0,047,tab 1) at HRT and superior RNFL thickness (p=0,01), temporal and inferior inner macular thickness (p=0,03) at OCT. Differences in the pVep latencies were found at 3 and 8 months after birth, but not at the time of morphological examination. Steady State pVEP amplitudes differences were not statistically significant. Conclusion Morphologic optic disk and macula differences between term and preterm children seems not functionally affect the visual pathway. [source] Macular thickness alterations after cataract surgery determined by optical coherence tomographyACTA OPHTHALMOLOGICA, Issue 2009M ELEFTHERIADOU Purpose To evaluate macular thickness alterations with optical coherence tomography after phacoemulsification and posterior champer intraocular lens implantation. Methods In this prospective study,201 patients who underwent phacoemulsication(102 men and 99 women)with mean age 65±8years were included.Best corrected visual acuity,complete slit lamp examination with lens and OCT examination were performed in all patients before surgery and at one,three and six months postoperatively.Patients were divided into five groups:Group 1(control group-100 eyes):patients without any predisponding factors for cystoid macular edema,Group 2(15 eyes):patients with complicated surgery,Group 3(27 eyes):patients with epiretinal membrane,Group 4(35 eyes):patients with diabetes and Group 5(24 eyes):patients with glaucoma. Results The preoperative mean minimal foveal thickness(MMFT)in groups 1 and 2 was 204±24,m and 213±47,m respectively and had no significant changes throughout the follow up period(p>0,05). In groups 3,4 and 5 a significant increase of macular thickness was detected. In group 3 the preoperative MMTF was 248±72,m and at 1,3 and 6 months it was 263±86,m(p=0,01),240±30,m(p=0,18)and 270±64,m(p<0,01)respectively. In group 4 the preoperative MMTF was 219±39,m,after 1month the MMTF increased at 257±78,m(p=0,002),at 3months it was 231±46,m(p=0,005)and at the last examination at 6 months it was 236±49,m(p=0,005). In group 5 the initially MMTF(206±21,m)had significant increase in the first[213±30,m(p=0,07)]and in the third month[223±24,m(p=0,03)]. Conclusion Diabetic retinopathy, epiretinal membranes and glaucoma may predispose to increase in macular thickness after cataract surgery. [source] Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusionACTA OPHTHALMOLOGICA, Issue 1 2009Florian Rensch Abstract. Purpose:, To evaluate the effect of early intravitreal bevacizumab injections for the treatment of macular oedema caused by non-ischaemic central retinal vein occlusion (CRVO). Methods:, The study included 25 patients (25 eyes) with macular oedema caused by non-ischaemic central retinal vein occlusion, who received three intravitreal injections of 1.5 mg bevacizumab with an interval of 6 weeks between the injections. Mean duration of central retinal vein occlusion prior to the first injection was 4.2 ± 3.6 days. All patients were re-examined 1, 3 and 6 months after the first injection. The main outcome parameters were visual acuity and macular thickness, as measured by optical coherence tomography. Results:, Mean visual acuity improved significantly from 0.97 ± 0.40 logMAR at baseline to 0.70 ± 0.42 logMAR (P = 0.007) at 1 month, 0.69 ± 0.46 (P = 0.006) 3 months and 0.69 ± 0.52 (P = 0.015) 6 months after the first injection. Mean central retinal thickness decreased significantly from 530 ± 152 ,m at baseline to 347 ± 127 ,m (P < 0.001) at 1 month, 370 ± 165 ,m (P < 0.001) 3 months and 346 ± 129 ,m (P < 0.001) 6 months (P < 0.001) after the first injection. The increase in visual acuity correlated significantly (P < 0.01) with the decrease in macular thickness. Mean intraocular pressure was 14.2 ± 3.2 mmHg at baseline and did not differ significantly from the measurement obtained at 1 month (P = 0.59), 3 months (P = 0.88) and 6 months after the first injection (P = 0.65). Conclusion:, Intravitreal bevacizumab injections given shortly after onset of non-ischaemic central retinal vein occlusion may result in a significant increase in vision and a corresponding decrease in macular oedema. [source] Apolipoprotein E genotype and risk for development of cataract and age-related macular degenerationACTA OPHTHALMOLOGICA, Issue 4 2008Øygunn A. Utheim Abstract. Purpose:, To study whether apolipoprotein E (APOE) genotypes are associated with risk for developing cataract and age-related macular degeneration (AMD). Methods:, A sample of 88 healthy adults (50,75 years) genotyped for polymorphisms of APOE underwent an eye examination which included visual acuity (VA) testing, slit-lamp cataract evaluation, optical coherence tomography (OCT) and fundus photography, the last of which was analysed and graded for macular pathology at the Reading Centre, Moorfields Eye Hospital, London. Two-by-two cross tables were analysed using the Fisher,Boschloo unconditional full multinomial test. Two-sample t -tests were used for comparing means of scale variables. Results:, Thirty-two participants were diagnosed with cataract or had undergone cataract surgery in one or both eyes, and 56 participants demonstrated no signs of cataract. We found that APOE4 carriers were less likely to have cataract than non-APOE4 carriers (p = 0.039). No correlation between APOE genotypes and morphologic changes in the macular region was revealed. However, APOE3 carriers disclosed significantly higher average macular thickness in both eyes than non-APOE3 carriers (p = 0.012), and APOE3 carriers also had significantly better VA than non-APOE3 carriers (p = 0.041). Conclusions:, We found no association between AMD and APOE polymorphism in a population of 96 individuals aged 50,75 years. A weak negative association between APOE4 and cataract was uncovered in the same population. Apolipoprotein E3 may be a protective factor against the loss of nerve fibres in the macular region. [source] Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trialCLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 6 2010Mark C Gillies FRANZCO PhD Abstract Purpose:, To describe the 3-year risk of cataract after intravitreal triamcinolone (IVTA) injections for diabetic macular oedema and the outcomes of cataract surgery. Methods:, Prospective data from a randomized clinical trial were analysed. At baseline, 27 phakic eyes with diabetic macular oedema were randomized to receive IVTA and 25 to receive sham injection. After 2 years, initial sham-treated eyes were eligible to receive IVTA as the study became open label for the third year. The cumulative incidence of cataract surgery was the primary outcome of the study. Other outcomes assessed included progression of cataract, best-corrected logarithm of the minimal angle of resolution visual acuity before and after surgery and central macular thickness. Results:, Over the 3 years of the study, 15/27 (56%) phakic eyes in the IVTA treated group underwent cataract surgery as compared with 2/25 (8%) initial sham-treated eyes (P < 0.001). Mean visual acuity 6 months after cataract surgery was better than at entry into the trial. Two (15%) of the eyes in the IVTA-treated group undergoing cataract surgery had a loss of >15 letters. In the IVTA-treated group, 10/15 (67%) eyes that had three or more injections had progression of posterior subcapsular cataract by ,2 grades as compared with only 2/12 (17%) eyes that had fewer than three injections (P = 0.009). Conclusions:, Over half of the eyes receiving IVTA injections for diabetic macular oedema required cataract surgery within 3 years. In eyes with three or more IVTA injections, two-thirds had progression of posterior subcapsular cataract. Visual outcomes after cataract surgery were generally good, although a small proportion of eyes lost greater than 15 letters over the course of the study. [source] Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusionCLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 5 2009Sung P Park MD Abstract Background:, To investigate sequential changes of aqueous vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in macular oedema secondary to branch retinal vein occlusion (BRVO) following intravitreal injection of bevacizumab (IVB). Methods:, We recruited 10 healthy controls and 40 patients with BRVO. Aqueous levels of VEGF and PEDF were measured by ELISA at the time of IVB and 6 weeks later. Non-response to IVB was defined as showing persistent macular oedema based on reduction of central macular thickness by less than 20% from baseline measurements by optical coherence tomography and vision improvement by <0.3 logMAR at 6 weeks after IVB. Fluorescein angiography was performed after resolution of foveal haemorrhage. We compared aqueous levels of VEGF and PEDF between responders and non-responders. Results:, The aqueous levels of VEGF and PEDF were significantly higher in 16 non-responders than in 24 responders at baseline measurements (491 ± 231 pg/mL vs. 250 ± 112 pg/mL, P < 0.001; 32 ± 4 ng/mL vs. 25 ± 5 ng/mL, P < 0.001, respectively). Six weeks after IVB, the aqueous levels of VEGF and PEDF were still higher in non-responders than in responders (388 ± 141 pg/mL vs. 104 ± 40 pg/mL, P < 0.001; 30 ± 8 ng/mL vs. 18 ± 5 ng/mL, P < 0.001, respectively). Fluorescein angiography revealed that non-responders showed higher frequencies of macular ischaemia and ischaemic BRVO. Conclusions:, Our results indicate that aqueous VEGF levels are associated with persistent macular oedema secondary to ischaemic BRVO following IVB. [source] | ||||||||||